1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key benefits for the stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Process
3. EXECUTIVE SUMMARY
3.1. Key Findings
3.2. Analyst View
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Russia-Ukraine War Impact Analysis
5. GLOBAL ANTIBODY DRUG CONJUGATES MARKET BY PRODUCT TYPE
5.1. Introduction
5.2. Adcetris
5.2.1. Market Trends and Opportunities
5.2.2. Growth Prospects
5.2.3. Geographic Lucrativeness
5.3. Kadcyla
5.3.1. Market Trends and Opportunities
5.3.2. Growth Prospects
5.3.3. Geographic Lucrativeness
5.4. Other Product Types
5.4.1. Market Trends and Opportunities
5.4.2. Growth Prospects
5.4.3. Geographic Lucrativeness
6. GLOBAL ANTIBODY DRUG CONJUGATES MARKET BY TARGET TYPE
6.1. Introduction
6.2. Cd30 Antibiotics
6.2.1. Market Trends and Opportunities
6.2.2. Growth Prospects
6.2.3. Geographic Lucrativeness
6.3. Her2 Antibiotics
6.3.1. Market Trends and Opportunities
6.3.2. Growth Prospects
6.3.3. Geographic Lucrativeness
6.4. Others
6.4.1. Market Trends and Opportunities
6.4.2. Growth Prospects
6.4.3. Geographic Lucrativeness
7. GLOBAL ANTIBODY DRUG CONJUGATES MARKET BY TECHNOLOGY
7.1. Introduction
7.2. Cleavable Linker
7.2.1. Market Trends and Opportunities
7.2.2. Growth Prospects
7.2.3. Geographic Lucrativeness
7.3. Non-Cleavable Linker
7.3.1. Market Trends and Opportunities
7.3.2. Growth Prospects
7.3.3. Geographic Lucrativeness
8. GLOBAL ANTIBODY DRUG CONJUGATES MARKET BY APPLICATION
8.1. Introduction
8.2. Breast Cancer
8.2.1. Market Trends and Opportunities
8.2.2. Growth Prospects
8.2.3. Geographic Lucrativeness
8.3. Blood Cancer
8.3.1. Market Trends and Opportunities
8.3.2. Growth Prospects
8.3.3. Geographic Lucrativeness
8.4. Urinary Tract/Bladder Cancer
8.4.1. Market Trends and Opportunities
8.4.2. Growth Prospects
8.4.3. Geographic Lucrativeness
8.5. Cervical and Head & Neck Cancer
8.5.1. Market Trends and Opportunities
8.5.2. Growth Prospects
8.5.3. Geographic Lucrativeness
9. GLOBAL ANTIBODY DRUG CONJUGATES MARKET BY END-USER
9.1. Introduction
9.2. Hospitals
9.2.1. Market Trends and Opportunities
9.2.2. Growth Prospects
9.2.3. Geographic Lucrativeness
9.3. Clinics
9.3.1. Market Trends and Opportunities
9.3.2. Growth Prospects
9.3.3. Geographic Lucrativeness
9.4. Others
9.4.1. Market Trends and Opportunities
9.4.2. Growth Prospects
9.4.3. Geographic Lucrativeness
10. GLOBAL ANTIBODY DRUG CONJUGATES MARKET BY GEOGRAPHY
10.1. Introduction
10.2. North America
10.2.1. By Product Type
10.2.2. By Target Type
10.2.3. By Technology
10.2.4. By Application
10.2.5. By End-User
10.2.6. By Country
10.2.6.1. USA
10.2.6.1.1. Market Trends and Opportunities
10.2.6.1.2. Growth Prospects
10.2.6.2. Canada
10.2.6.2.1. Market Trends and Opportunities
10.2.6.2.2. Growth Prospects
10.2.6.3. Mexico
10.2.6.3.1. Market Trends and Opportunities
10.2.6.3.2. Growth Prospects
10.3. South America
10.3.1. By Product Type
10.3.2. By Target Type
10.3.3. By Technology
10.3.4. By Application
10.3.5. By End-User
10.3.6. By Country
10.3.6.1. Brazil
10.3.6.1.1. Market Trends and Opportunities
10.3.6.1.2. Growth Prospects
10.3.6.2. Argentina
10.3.6.2.1. Market Trends and Opportunities
10.3.6.2.2. Growth Prospects
10.3.6.3. Others
10.3.6.3.1. Market Trends and Opportunities
10.3.6.3.2. Growth Prospects
10.4. Europe
10.4.1. By Product Type
10.4.2. By Target Type
10.4.3. By Technology
10.4.4. By Application
10.4.5. By End-User
10.4.6. By Country
10.4.6.1. United Kingdom
10.4.6.1.1. Market Trends and Opportunities
10.4.6.1.2. Growth Prospects
10.4.6.2. Germany
10.4.6.2.1. Market Trends and Opportunities
10.4.6.2.2. Growth Prospects
10.4.6.3. France
10.4.6.3.1. Market Trends and Opportunities
10.4.6.3.2. Growth Prospects
10.4.6.4. Spain
10.4.6.4.1. Market Trends and Opportunities
10.4.6.4.2. Growth Prospects
10.4.6.5. Others
10.4.6.5.1. Market Trends and Opportunities
10.4.6.5.2. Growth Prospects
10.5. Middle East and Africa
10.5.1. By Product Type
10.5.2. By Target Type
10.5.3. By Technology
10.5.4. By Application
10.5.5. By End-User
10.5.6. By Country
10.5.6.1. Saudi Arabia
10.5.6.1.1. Market Trends and Opportunities
10.5.6.1.2. Growth Prospects
10.5.6.2. UAE
10.5.6.2.1. Market Trends and Opportunities
10.5.6.2.2. Growth Prospects
10.5.6.3. Others
10.5.6.3.1. Market Trends and Opportunities
10.5.6.3.2. Growth Prospects
10.6. Asia Pacific
10.6.1. By Product Type
10.6.2. By Target Type
10.6.3. By Technology
10.6.4. By Application
10.6.5. By End-User
10.6.6. By Country
10.6.6.1. China
10.6.6.1.1. Market Trends and Opportunities
10.6.6.1.2. Growth Prospects
10.6.6.2. Japan
10.6.6.2.1. Market Trends and Opportunities
10.6.6.2.2. Growth Prospects
10.6.6.3. India
10.6.6.3.1. Market Trends and Opportunities
10.6.6.3.2. Growth Prospects
10.6.6.4. South Korea
10.6.6.4.1. Market Trends and Opportunities
10.6.6.4.2. Growth Prospects
10.6.6.5. Others
10.6.6.5.1. Market Trends and Opportunities
10.6.6.5.2. Growth Prospects
11. COMPETITIVE ENVIRONMENT AND ANALYSIS
11.1. Major Players and Strategy Analysis
11.2. Market Share Analysis
11.3. Mergers, Acquisitions, Agreements, and Collaborations
11.4. Competitive Dashboard
12. COMPANY PROFILES
12.1. The Linde Group
12.2. Astrazeneca
12.3. Pfizer, Inc (Seagen, Inc.)
12.4. GSK Plc
12.5. Takeda Pharmaceutical Company Ltd.
12.6. F. Hoffmann-La Roche Ltd. (Genentech Inc.)
12.7. Novartis
12.8. Gilead Sciences, Inc.
12.9. Sanofi S.A.
12.10. Daiichi Sankyo Company Ltd.
12.11. AbbVie (Immunogen Inc.)
12.12. Lantheus
12.13. Bayer Healthcare Pharmaceuticals
12.14. Astellas Pharma
12.15. Synthon Holding BV